National Institute of Health

Rome, Italy

National Institute of Health

Rome, Italy
SEARCH FILTERS
Time filter
Source Type

News Article | May 14, 2017
Site: www.prnewswire.com

The Impact of Cycling on Men's Sexual and Urinary Functions (#PD45-05): Researchers conducted a survey of male athletes recruited from English-speaking sports clubs throughout the world. The study included nearly 4,000 participants, of whom 63 percent were cyclists who did not swim or run and 37 percent were swimmers or runners who did not cycle. Participants were queried about their physical activity and answered validated questionnaires including: The Sexual Health Inventory for Men (SHIM), International Prostate Symptom Score (I-PSS) and the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI). High intensity cycling was defined as cycling for longer than two years, more than three times per week and a daily average of more than 25 miles. The Impact of Cycling on Women's Sexual and Urinary Functions (# PD44-03): Researchers also conducted an international study on female athletes recruited from English-speaking sports clubs to determine if cycling has an effect on the female genitourinary tract. The study included 2,691 participants. Thirty-nine percent (658) were cyclists and 61 percent (1,013) were swimmers or runners who did not regularly cycle. Participants answered questions about their physical activities, sexual function, urinary symptoms, history of urinary tract infections (UTI) and perineal numbness using the Female Sexual Function Inventory (FSFI) and the I-PSS. As cycling gains in popularity, as both a hobby and a professional sport, it is important for the public to know that it has no credible link to urologic disease or sexual dysfunction," says Dr. McVary. "Men and women can benefit from the cardiovascular exercise of cycling without worrying about negative side effects to their urinary tract or sexual performance." NOTE TO REPORTERS: Experts are available to discuss this study outside normal briefing times. To arrange an interview with an expert, please contact the AUA Communications Office at 410-689-3932 or e-mail cfrey@AUAnet.org. About the American Urological Association: The 112th Annual Meeting of the American Urological Association takes place May 12 – 16 at the Boston Convention & Exhibition Center in Boston, MA. Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 21,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/does-cycling-affect-mens-and-womens-sexual-health-and-urinary-functions-300456701.html


News Article | May 10, 2017
Site: www.techradar.com

To meet the surging demand for expertise in the field of artificial intelligence (AI), US-based manufacturer of graphics processor technologies NVIDIA on Tuesday announced it will train 100,000 developers this year via the NVIDIA Deep Learning Institute. The NVIDIA Deep Learning Institute provides developers, data scientists and researchers with practical training on the use of the latest AI tools and technology. "AI is the defining technology of our generation. To meet overwhelming demand from enterprises, government agencies and universities, we are dramatically expanding the breadth and depth of our offerings, so developers worldwide can learn how to leverage this transformative technology," said Greg Estes, Vice President of Developer Programmes at NVIDIA, in a statement. Analyst firm International Data Corporation (IDC) estimates that 80 percent of all applications will have an AI component by 2020. The NVIDIA institute has trained developers around the world at public events and onsite training at companies such as Adobe, Alibaba and SAP and at government research institutions like the US National Institute of Health, National Institute of Science and Technology and the Barcelona Supercomputing Centre. It has also trained developers at the institutes of higher learning such as Temasek Polytechnic Singapore and India Institute of Technology, Bombay. NVIDIA is broadening the Deep Learning Institute's curriculum to include the applied use of deep learning for self-driving cars, healthcare, web services, robotics, video analytics and financial services. "There is a real demand for developers who not only understand artificial intelligence, but know how to apply it in commercial applications," added Christian Plagemann, Vice President of Content at Udacity. NVIDIA is also working with Microsoft Azure, IBM Power and IBM Cloud teams to port lab content to their cloud solutions.


News Article | May 10, 2017
Site: www.marketwired.com

KELOWNA, BC--(Marketwired - May 10, 2017) - Lexaria Bioscience Corp ( : LXRP) ( : LXX) (the "Company", "Lexaria") announces plans for research and formulation development ("R&D") on nonsteroidal anti-inflammatory drugs ("NSAIDs") utilizing its patented technology and as provisioned within its previously announced 2017 & 2018 R&D program. Lexaria will conduct in vitro absorption studies utilizing the Company's technology to examine improvements in absorption across human intestinal tissue, which is expected to be followed by in vivo (animal) studies to confirm the Company's hypothesis regarding first-pass liver metabolism. The Company postulates that its technology may enable oral delivery of NSAIDs without encountering first-pass liver metabolism, which has the potential to greatly reduce corresponding liver damage. Pain-relief drugs are comprised mostly of NSAIDs and of opioids and represented a $36.6 billion market in 2014. (MSP, BCC Research - The Global Market for Pain Management Drugs and Devices, September 2015) Long term use or overuse of NSAID's has been associated with chronic liver conditions that can be debilitating and even cause death. Common generic forms of NSAIDS are products such as Aspirin, Ibuprofen, Naproxen, Diclofenac and others. Acetaminophen is sometimes included within this list. More effective absorption of NSAIDS may also lead to more effective pain killing properties, thus allowing for fewer opioid medication prescriptions. Prescription based opioid medications are responsible for nearly 18,000 deaths annually in the USA. (National Institute of Health) Lexaria has a total of 18 patents pending -- including the delivery of NSAIDs -- and patent applications filed in more than 40 countries worldwide. Separately, Lexaria also announces it has received US$34,753.40 from the exercise of warrants previously granted. The stock warrants were exercised at prices of US$0.2273 and US$0.1818, for a total of 156,750 common shares being issued. All warrants are being exercised by third parties who are neither officers nor directors of the Company. No commissions or placement fees have been paid related to the funds received from this warrant exercise. Proceeds will be used for general corporate purposes. Lexaria extends its thanks to its loyal shareholders for their continued support. The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company's technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. Plans can change thus there is no assurance that any currently planned R&D will in fact occur, or that any R&D will provide successful or useful data or results. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements, nor that Lexaria's technology will deliver any improvement in taste or bioavailability with any reliability nor across any product category. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any hemp oil or cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever, nor that any patent application in the USA or any other nation or under any treaty will result in the award of an actual patent; nor that an award of any actual patent will protect against challenges from unknown third parties. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA)or by Health Canada. Lexaria products are not intended to diagnose, treat, cure or prevent any disease. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.


"Since my Rezūm procedure, I've been free from having to know where the bathroom is right away," said patient James Huber. "It worked beautifully and there have been no side effects. I don't have to take pills, and don't have to pay for them. The end result is freedom, and when you're 75, that becomes a really important issue. It gives you the freedom you never thought you would have again." "Based on the conservation of sexual function and efficacy in treating LUTS/BPH, Rezūm could be offered as first-line treatment in lieu of drugs for patients with moderate to severe LUTS," said Dr. Kevin McVary, professor and chair, Division of Urology, Southern Illinois University School of Medicine in Springfield, Ill. BPH is one of the top 10 most common and costly diseases in the U.S., affecting more than 12 million American men aged 50 or older, with nearly 800,000 new diagnoses each year. BPH causes significant quality of life issues including waking up multiple times during the night to urinate, frequency, urgency, irregular and weak urinary flow, anxiety, challenges with sexual function and limitation in daily activities. The Rezūm System uses radiofrequency current to create thermal energy that is convectively delivered to obstructive prostate tissue through targeted, precise treatments. The treated tissue is then resorbed by the body's immune system which alleviates the symptoms of BPH and improves patients' quality of life and ability to urinate, while preserving sexual function. Urology experts will present five abstracts reporting the data from clinical studies they conducted on the Rezūm System to treat BPH during the 2017 American Urological Association (AUA) annual meeting in Boston May 13 - 15, 2017. These presentations will include Dr. Claus Roehrborn, chair of UT Southwestern Urology Department, presenting the two-year outcomes from the company's randomized controlled, level one pivotal study of the Rezūm System to relieve LUTS caused by BPH. Dr. Nikhil Gupta of Southern Illinois University will present clinical data demonstrating the effectiveness of the Rezūm System to treat BPH in (i) obese men, while preserving erectile and ejaculatory function (which received the "Best Abstract Award" from the AUA), (ii) men who are in retention as a result of their BPH, and (iii) men compared to the outcomes data from the National Institute of Health sponsored "Medical Therapy of Prostatic Symptoms" (MTOPS) study. In addition, Dr. Tobias Köhler, most recently of Southern Illinois University and now of The Mayo Clinic, will present the Rezūm procedure as part of the Plenary Prime Time BPH Surgical Techniques session. For more information about the Rezūm System, visit www.Rezūm.com. NxThera pioneered its convective radiofrequency thermotherapy platform technology to treat a variety of endourological conditions, beginning with BPH. NxThera's FDA-cleared Rezūm System is a next-generation transurethral needle ablation system using radiofrequency to create thermal energy that is convectively delivered to obstructive prostate tissue in targeted, precise thermotherapy treatments, with minimal discomfort, to improve the symptoms of BPH and quality of life. Founded in 2008, NxThera is located in Maple Grove, Minn. For more information, visit www.Rezūm.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nxthera-reaches-milestone-of-10000-patients-effectively-treated-for-enlarged-prostate-with-minimally-invasive-rezm-system-300454131.html


News Article | May 9, 2017
Site: globenewswire.com

Support Potential of ADX71441 to treat Irritable Bowel  Syndrome, Interstitial Cystitis and Painful Bladder Syndrome Geneva, Switzerland, 9 May 2017 - Addex Therapeutics (SIX: ADXN) announced today positive results from multiple preclinical studies of ADX71441, a positive allosteric modulator (PAM) of the gamma-aminobutyric acid subtype B (GABAB) receptor, in models of visceral hyperalgesia. The studies were led by Prof. Jyoti N. Sengupta at the Medical College of Wisconsin, with the support of a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the US National Institute of Health. The findings strongly support the potential of ADX71441 in treating hyperalgesia in colonic inflammation (colitis) and bladder inflammation (cystitis). Chronic visceral pain syndromes related to the gastrointestinal or urinary tract represent an important unmet medical need as they can significantly impact the patient's quality of life. "These data represent an important step forward in the understanding of the role played by GABAB receptors in visceral pain and the potential of ADX71441 in large unmet medical needs, such as irritable bowel syndrome, interstitial cystitis and painful bladder syndrome," said Sonia Poli, CSO of Addex. "We look forward to continuing our collaboration with Prof Sengupta's group, and further evaluating the possibility of conducting clinical trials for ADX71441 in these compelling indications." The effect of ADX71441 was studied in reliable, reproducible and quantifiable preclinical models of visceral pain, which included behavioral measurements and electrophysiology recordings(1). Visceral motor reflex after colorectal distension (CRD) and urinary bladder distension (UBD) was significantly decreased (p<0.05) following systemic administration of ADX71441 (5, 10 and 50 mg/kg ip). The visceral analgesic effect of ADX71441 did not affect the normal function of the bladder as assessed by cystometry. In electrophysiology experiments, ADX71441 demonstrated significant inhibition of the response of UBD responsive lumbo-sacral (LS) spinal dorsal horn neurons to graded bladder distension. The effect was observed in spinal intact rats, but not in cervical (C1-C2) spinal transected rats. It also produced a moderate decrease in the spontaneous firing of these neurons in spinal intact rats. ADX71441 had no effect on the mechano-transduction properties or the spontaneous firing of UBD-sensitive pelvic nerve afferent (PNA) fibers. The current behavioral experiments to assess pain and the electrophysiology results indicate that ADX71441 produces visceral analgesia in animal models of cystitis and colitis.  The results indicate that ADX71441 produces this analgesic effect primarily by acting at the supra-spinal sites without affecting bladder motility. "We thank the NIDDK for their support and Prof. Sengupta and his team for their dedication to this important research with ADX71441," commented Tim Dyer, CEO of Addex. "These compelling results are a further example of how we are leveraging our collaborations with leading academic institutions to better understand the potential of the promising candidates in our pipeline." About GABA B receptor The GABAB receptor is clinically & commercially validated. Generic GABAB receptor agonist, baclofen, is marketed for spasticity and some spinal cord injuries, and French health authorities have approved its use for the treatment of alcoholism. Baclofen is also used off label for a number of other indications including overactive bladder (OAB), but its utility is limited due to variety of side effects and rapid clearance, requiring frequent administration of higher doses. About ADX71441 ADX71441 is a potent selective positive allosteric modulator (PAM) which potentiates GABA responses at the GABAB receptor. ADX71441 is a novel, first-in-class, oral, small molecule that demonstrated excellent preclinical efficacy and tolerability in rodent models of pain, anxiety, OAB, alcohol use disorders, nicotine dependence and in a non-human primate model of cocaine use disorder. ADX71441 has also proven efficacy in a genetic model of Charcot-Marie-Tooth Type 1A disease (CMT1A). ADX71441 has a different molecular mechanism from the generic drug baclofen in that it is a positive allosteric modulator, rather than an orthosteric agonist at the GABAB receptor, with a longer half-life, suitable for once daily administration. ADX71441 only acts when the natural ligand (GABA) activates the receptor, therefore respecting the physiological cycle of activation. It has been proposed that PAMs produce less adverse effects and lead to less tolerance than direct agonists. Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start Phase 1 and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), cocaine and alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM, mGluR7NAM, TrkBPAM and mGluR3NAM & PAM. Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


News Article | May 9, 2017
Site: globenewswire.com

Support Potential of ADX71441 to treat Irritable Bowel  Syndrome, Interstitial Cystitis and Painful Bladder Syndrome Geneva, Switzerland, 9 May 2017 - Addex Therapeutics (SIX: ADXN) announced today positive results from multiple preclinical studies of ADX71441, a positive allosteric modulator (PAM) of the gamma-aminobutyric acid subtype B (GABAB) receptor, in models of visceral hyperalgesia. The studies were led by Prof. Jyoti N. Sengupta at the Medical College of Wisconsin, with the support of a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the US National Institute of Health. The findings strongly support the potential of ADX71441 in treating hyperalgesia in colonic inflammation (colitis) and bladder inflammation (cystitis). Chronic visceral pain syndromes related to the gastrointestinal or urinary tract represent an important unmet medical need as they can significantly impact the patient's quality of life. "These data represent an important step forward in the understanding of the role played by GABAB receptors in visceral pain and the potential of ADX71441 in large unmet medical needs, such as irritable bowel syndrome, interstitial cystitis and painful bladder syndrome," said Sonia Poli, CSO of Addex. "We look forward to continuing our collaboration with Prof Sengupta's group, and further evaluating the possibility of conducting clinical trials for ADX71441 in these compelling indications." The effect of ADX71441 was studied in reliable, reproducible and quantifiable preclinical models of visceral pain, which included behavioral measurements and electrophysiology recordings(1). Visceral motor reflex after colorectal distension (CRD) and urinary bladder distension (UBD) was significantly decreased (p<0.05) following systemic administration of ADX71441 (5, 10 and 50 mg/kg ip). The visceral analgesic effect of ADX71441 did not affect the normal function of the bladder as assessed by cystometry. In electrophysiology experiments, ADX71441 demonstrated significant inhibition of the response of UBD responsive lumbo-sacral (LS) spinal dorsal horn neurons to graded bladder distension. The effect was observed in spinal intact rats, but not in cervical (C1-C2) spinal transected rats. It also produced a moderate decrease in the spontaneous firing of these neurons in spinal intact rats. ADX71441 had no effect on the mechano-transduction properties or the spontaneous firing of UBD-sensitive pelvic nerve afferent (PNA) fibers. The current behavioral experiments to assess pain and the electrophysiology results indicate that ADX71441 produces visceral analgesia in animal models of cystitis and colitis.  The results indicate that ADX71441 produces this analgesic effect primarily by acting at the supra-spinal sites without affecting bladder motility. "We thank the NIDDK for their support and Prof. Sengupta and his team for their dedication to this important research with ADX71441," commented Tim Dyer, CEO of Addex. "These compelling results are a further example of how we are leveraging our collaborations with leading academic institutions to better understand the potential of the promising candidates in our pipeline." About GABA B receptor The GABAB receptor is clinically & commercially validated. Generic GABAB receptor agonist, baclofen, is marketed for spasticity and some spinal cord injuries, and French health authorities have approved its use for the treatment of alcoholism. Baclofen is also used off label for a number of other indications including overactive bladder (OAB), but its utility is limited due to variety of side effects and rapid clearance, requiring frequent administration of higher doses. About ADX71441 ADX71441 is a potent selective positive allosteric modulator (PAM) which potentiates GABA responses at the GABAB receptor. ADX71441 is a novel, first-in-class, oral, small molecule that demonstrated excellent preclinical efficacy and tolerability in rodent models of pain, anxiety, OAB, alcohol use disorders, nicotine dependence and in a non-human primate model of cocaine use disorder. ADX71441 has also proven efficacy in a genetic model of Charcot-Marie-Tooth Type 1A disease (CMT1A). ADX71441 has a different molecular mechanism from the generic drug baclofen in that it is a positive allosteric modulator, rather than an orthosteric agonist at the GABAB receptor, with a longer half-life, suitable for once daily administration. ADX71441 only acts when the natural ligand (GABA) activates the receptor, therefore respecting the physiological cycle of activation. It has been proposed that PAMs produce less adverse effects and lead to less tolerance than direct agonists. Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start Phase 1 and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), cocaine and alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM, mGluR7NAM, TrkBPAM and mGluR3NAM & PAM. Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


SYNOPSIS: In the early 90s, a mysterious muscular disease with symptoms that included severe muscle and joint pain began to surface among patients in France. Doctors in Paris discovered that these patients had developed a new disease called Macrophagic Myofascitis, or MMF, which occurs when the aluminum hydroxide adjuvant from a vaccine remains embedded in the muscle tissue. What the pharmaceutical companies don't reveal is that the aluminum adjuvant was never rigorously tested before going on the market and there are alternative, much less toxic, adjuvants available. Featuring interviews with patients, doctors, scientists, and influential politicians, Injecting Aluminum examines aluminum's devastating effects on the human body and calls into question the public health policies around aluminum in vaccines. Directed by Marie-Ange Poyet, Injecting Aluminum features groundbreaking interviews with leading aluminum specialists such as "Mr. Aluminum", Dr. Christopher Exley, PhD in the Ecotoxicology of Aluminum, Dr. Yehuda Shoenfeld, founder of the leading Centre for Autoimmune Diseases at the Sheba Medical Center, Dr. Romain Gherardi, the Director of the French National Institute of Health and Medical Research, and Dr. Jérôme Authier, neurologist and head of the Center of Reference of neuromuscular diseases of the Henri Mondor Hospital in Créteil, France. Injecting Aluminum has a running time of 90 minutes, and is not rated. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/toxic-impact-of-aluminum-in-vaccines-investigated-in-new-documentary-injecting-aluminum-300456303.html


News Article | May 9, 2017
Site: globenewswire.com

Support Potential of ADX71441 to treat Irritable Bowel  Syndrome, Interstitial Cystitis and Painful Bladder Syndrome Geneva, Switzerland, 9 May 2017 - Addex Therapeutics (SIX: ADXN) announced today positive results from multiple preclinical studies of ADX71441, a positive allosteric modulator (PAM) of the gamma-aminobutyric acid subtype B (GABAB) receptor, in models of visceral hyperalgesia. The studies were led by Prof. Jyoti N. Sengupta at the Medical College of Wisconsin, with the support of a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the US National Institute of Health. The findings strongly support the potential of ADX71441 in treating hyperalgesia in colonic inflammation (colitis) and bladder inflammation (cystitis). Chronic visceral pain syndromes related to the gastrointestinal or urinary tract represent an important unmet medical need as they can significantly impact the patient's quality of life. "These data represent an important step forward in the understanding of the role played by GABAB receptors in visceral pain and the potential of ADX71441 in large unmet medical needs, such as irritable bowel syndrome, interstitial cystitis and painful bladder syndrome," said Sonia Poli, CSO of Addex. "We look forward to continuing our collaboration with Prof Sengupta's group, and further evaluating the possibility of conducting clinical trials for ADX71441 in these compelling indications." The effect of ADX71441 was studied in reliable, reproducible and quantifiable preclinical models of visceral pain, which included behavioral measurements and electrophysiology recordings(1). Visceral motor reflex after colorectal distension (CRD) and urinary bladder distension (UBD) was significantly decreased (p<0.05) following systemic administration of ADX71441 (5, 10 and 50 mg/kg ip). The visceral analgesic effect of ADX71441 did not affect the normal function of the bladder as assessed by cystometry. In electrophysiology experiments, ADX71441 demonstrated significant inhibition of the response of UBD responsive lumbo-sacral (LS) spinal dorsal horn neurons to graded bladder distension. The effect was observed in spinal intact rats, but not in cervical (C1-C2) spinal transected rats. It also produced a moderate decrease in the spontaneous firing of these neurons in spinal intact rats. ADX71441 had no effect on the mechano-transduction properties or the spontaneous firing of UBD-sensitive pelvic nerve afferent (PNA) fibers. The current behavioral experiments to assess pain and the electrophysiology results indicate that ADX71441 produces visceral analgesia in animal models of cystitis and colitis.  The results indicate that ADX71441 produces this analgesic effect primarily by acting at the supra-spinal sites without affecting bladder motility. "We thank the NIDDK for their support and Prof. Sengupta and his team for their dedication to this important research with ADX71441," commented Tim Dyer, CEO of Addex. "These compelling results are a further example of how we are leveraging our collaborations with leading academic institutions to better understand the potential of the promising candidates in our pipeline." About GABA B receptor The GABAB receptor is clinically & commercially validated. Generic GABAB receptor agonist, baclofen, is marketed for spasticity and some spinal cord injuries, and French health authorities have approved its use for the treatment of alcoholism. Baclofen is also used off label for a number of other indications including overactive bladder (OAB), but its utility is limited due to variety of side effects and rapid clearance, requiring frequent administration of higher doses. About ADX71441 ADX71441 is a potent selective positive allosteric modulator (PAM) which potentiates GABA responses at the GABAB receptor. ADX71441 is a novel, first-in-class, oral, small molecule that demonstrated excellent preclinical efficacy and tolerability in rodent models of pain, anxiety, OAB, alcohol use disorders, nicotine dependence and in a non-human primate model of cocaine use disorder. ADX71441 has also proven efficacy in a genetic model of Charcot-Marie-Tooth Type 1A disease (CMT1A). ADX71441 has a different molecular mechanism from the generic drug baclofen in that it is a positive allosteric modulator, rather than an orthosteric agonist at the GABAB receptor, with a longer half-life, suitable for once daily administration. ADX71441 only acts when the natural ligand (GABA) activates the receptor, therefore respecting the physiological cycle of activation. It has been proposed that PAMs produce less adverse effects and lead to less tolerance than direct agonists. Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start Phase 1 and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), cocaine and alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM, mGluR7NAM, TrkBPAM and mGluR3NAM & PAM. Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


With an upcoming publication in the Worldwide Leaders in Healthcare, Dr. Angelia Cleark McDowell, DNP, MSN, BSN, APRN, PMHNP-BC, joins the prestigious ranks of the International Nurses Association. Angelia Cleark McDowell is a Nurse Practitioner with seven years of experience in her field and extensive expertise in all facets of nursing, especially mental health, inpatient rehabilitation, medical/surgical nursing, telemetry nursing, and corrections nursing. Angelia is currently serving as a psychiatric mental health nurse practitioner at an outpatient mental health facility in Southaven, Mississippi serving patients with an array of mental health care needs. Previously, Angelia worked with the Corrections Corporation of America  in Tutwiler, Mississippi as a staff nurse and staff RN on the inpatient rehabilitation unit at Northwest Mississippi Regional Medical Centers in Clarksdale, Mississippi. Angelia Cleark McDowell graduated with her Associate of Arts Degree in General Business in 2006 and her Associate Degree in Nursing in 2010 from Coahoma Community College in Clarksdale, Mississippi, where she received the Highest GPA Nursing Award. An advocate for continuing education, Angelia went on to receive her Bachelor of Science Degree in Nursing in 2012 from the University of Texas at Arlington, followed by her Master of Science Degree in Nursing with a Psychiatric Mental Health Nurse Practitioner specialty from the University of South Alabama in 2015. Angelia also received her Doctor of Nursing Practice Degree from University of South Alabama in 2016. Angelia is certified in EKG Interpretation and Tuberculosis Surveillance and Testing. Angelia also received a certification of completion from the United States Department of Health and Human Services, Health Resources and Services Administration for providing clinical care and services to underserved populations. She received certification from the National Institute of Health in 2013, as well as certification with the Collaborative Institutional Training Initiative in 2013. Angelia also holds certifications in Advanced Cardiovascular Life Support and Pediatric Advanced Life Support. To keep up to date with the latest advances and developments in her field, Angelia maintains a professional membership with the Mississippi Nurses Association, the National Scholars Honor Society, and the Sigma Theta Tau International Honor Society of Nursing. For her hard work and unwavering dedication, Angelia received an Award of Excellence for Mental Health Nursing, an Award of Excellence for Fundamentals of Nursing, and several Academic Excellence Awards for Academic Achievement by Coahoma Community College. She attributes her success to the support of her family, particularly her husband, who has been her greatest supporter and encourages her to supersede her own expectations. When she is not assisting her patients, Angelia enjoys reading, cooking, and physical fitness. Learn more about Dr. Angelia Cleark McDowell here: http://inanurse.org/network/index.php?do=/4122136/info/ and be sure to read her upcoming publication in the Worldwide Leaders in Healthcare.


The newly announced scientific board includes David Eagleman, PhD, Professor of Neuroscience, Stanford University, Founder & CSO, BrainCheck, and cofounder & CSO, NeoSensory; Christof Koch, PhD, CSO & President of Allen Institute for Brain Science; Emmanuel Mignot, MD, PhD, Director of Stanford Sleep Center; and Cedric Villani, PhD, winner of the 2010 Fields Medal and Director of Henri Poincarré Institute. These experts will help Rythm define its research strategy, encompassing sleep diagnosis, treatment, improvement, and understanding of the human brain. The human brain is the most complex organ in the known universe, and understanding the brain and sleep are among the biggest scientific challenges of the century. One-third of the population does not sleep well or sufficiently long. Currently, there are no obvious solutions to this epidemic. However, international research in neuroscience and Rythm are at the forefront of developing non-invasive solutions that are accurate and effective. The company is tackling multiple, ambitious challenges at the nexus of multiple disciplines: medicine, neurosciences, and mathematics. In forming a board, Rythm successfully sought to attract the best-of-the-best from across disciplines who are aligned with the company's mission and vision. "The brain is the most complex system known today, and within that field of study, sleep is a new domain that presents a variety of complex problems and solutions," said Hugo Mercier, CEO & Co-founder at Rythm. "The diversity of fields, experience, and intellect that the members of our board bring will help Rythm unlock major challenges and pursue the right research directions." David Eagleman is a professor at Stanford University in the department of Psychiatry & Behavioral Sciences, known for his work on brain plasticity, time perception, synesthesia, and neurolaw. He also serves as the Director of the Center for Science and Law. He is a Guggenheim Fellow, a council member in the World Economic Forum, and a popular TED speaker. He has launched two companies from his laboratory: NeoSensory and BrainCheck. He is a New York Times bestselling author published in 31 languages and is the writer and creator of the Emmy-nominated TV series, The Brain with David Eagleman. He is a renowned scientist with articles in all the major academic journals and profiles in national magazines such as the New Yorker. He is a regular commenter on national television and radio. "We don't yet fully understand why we sleep and dream, but we're aware that it's related to the consolidation of learning and memory," said Eagleman. "I am excited to work with Rythm to better unmask the mysteries and nuances of sleep state, and to be able to leverage that understanding to improve lives. Inadequate sleep prevents people from reaching their full potential. The improvement of sleep opens the hope of functioning at a more optimized mental performance." Christof Koch is a physicist turned neuroscientist serving as the President and Chief Scientific Officer of the Allen Institute for Brain Science in Seattle. He is leading a team of 300 scientists, engineers and staff engaged in a ten-year project that aims to understand the building blocks of the mammalian brain. Koch previously served as a professor at the California Institute of Technology for nearly 30 years, specializing in the biophysics of the brain and the neural bases of consciousness, and has been influential in arguing that consciousness can be approached using the modern tools of neurobiology. As a member of Rythm's board, Koch will contribute his neuroscientific expertise on how sleep relates to the brain and its electrical behavior in health and disease. "We have so much more to learn about the relationship that sleep has to the functioning of our brains and our health," said Koch. "Working with Rythm is an opportunity to bring academia together with the development of consumer products so that sleep research can become practicable." Emmanuel Mignot is the Craig Reynolds Professor of Sleep Medicine at Stanford Medical School and the Director of the Stanford Center for Sleep Sciences and Medicine. He is a recognized authority on sleep research and medicine, known primarily for his work on narcolepsy. He is a member of the National Academies of Sciences and Medicine and has received numerous research grants and honors, including National Institute of Health Research, Howard Hughes Medical Institute Investigator and McKnight Neuroscience awards. He is the co-author of more than 200 original scientific publications, and serves on the editorial board of scientific journals in the field of sleep and biology research. He formerly served as the president of the Sleep Research society, chair of the National Center on Sleep Disorders Research advisory board of the National institutes of Health, and chair of the Board of Scientific Counselors of the National Institute of Mental Health. "I've always been intrigued by the enigma of sleep and devoted my career to studying sleep disorders," said Mignot. "With the rapid growth of portable technology, biology and analytics, it is an exciting time for sleep, with plenty of opportunities to increase well-being. Rythm is bringing together people spanning multiple fields of science and technology to push forward our understanding of sleep and improve the diagnosis of sleep disorders. I look forward to contributing my knowledge and working with Rythm to help realize this vision." Cedric Villani is one of the world's most famous mathematicians who was awarded the Fields Medal, the world's most prestigious math award, in 2010. Currently, he is a professor at the University of Lyon and serves as the director of Pierre and Marie Curie University 's Institut Henri Poincaré. Villani's work focuses on partial differential equations, Riemannian geometry and mathematical physics. He received the Fields Medal for his work on Landau damping and the Boltzmann equation. He is also a well-known author and speaker, renowned for his passionate ability to make math exciting and accessible. Villani's expertise on computational mathematics and machine learning will be a valuable asset to Rythm because both areas are critical to the understanding of sleep and the brain. Until recently, machine learning mimicked brain functions, but now the new frontier is to understand how the brain works, and sleep represents an ideal entry door. This world class team serves as a validation of all the important work Rythm has done since 2014. The company is leveraging advancements in neuroscience, neurotechnology, artificial intelligence, and mathematics to propel sleep research and medicine forward and bring a real sleep solution to the market. This unique solution will introduce a whole new category of product that is efficient but non-invasive, and this demands a strong research effort and the development of sophisticated technology. The board is not only working with Rythm on diagnosis and treatment, but also to help build the product that will launch in Summer 2017. Rythm is a leading neurotechnology company. Bringing together the world's foremost experts in hardware, software, and neuroscience, Rythm builds consumer technology that stimulates brain function to enhance individual health and performance. The company's first product, Dreem, is sleep solution that uses brain activity and sound stimulation to increase the quality of sleep in a non-invasive way. Based in Paris and San Francisco, Rythm has raised substantial funding from investors, awards and government grants to support a world-class team of more than 70 people. For more information, visit www.dreem.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rythm-accelerates-sleep-research-and-neurotechnology-efforts-with-a-prestigious-scientific-advisory-board-and-advances-in-the-ai-xprize-competition-300456427.html

Loading National Institute of Health collaborators
Loading National Institute of Health collaborators